A Study to Evaluate the Food-Effect of H3B-6527

Phase 1 Completed 17 enrolled Eisai Inc. H3 Biomedicine Inc. · collab

NaSingle-groupOpen-labelBasic science

Summary

This study will be conducted to determine the effect of food on the relative bioavailability of H3B-6527 following administration of a H3B-6527 capsule with and without a meal.

Timeline

Start: 2017-12-27
Primary completion: 2018-01-27
Completion: 2018-01-27

Publications

Rioux N, Kim A, Nix D, Bowser T, Warmuth M, Smith PG, Schindler J. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. Cancer Chemother Pharmacol. 2019 Jan;83(1):91-96. doi: 10.1007/s00280-018-3708-3. Epub 2018 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	H3B-6527	Small molecule	200 mg	Oral

Indications

No indication recorded.